Clinical manifestations of systemic sclerosis (SS) accompanied with pulmonary involvement Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013
Disease course and outcome of progressive interstitial lung disease in systemic sclerosis Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new? Year: 2019
The natural course of systemic sclerosis patients with interstitial lung involvement Source: Eur Respir J 2005; 26: Suppl. 49, 336s Year: 2005
Interstitial lung disease with ANCA-associated vasculitis (AAV-ILD): Clinical features and survival compared to patients with ILD associated with systemic sclerosis and IPF Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020
Pulmonary physiology is poorly associated with radiological extent of disease in systemic sclerosis-associated interstitial lung disease Source: Eur Respir J, 53 (5) 1802182; 10.1183/13993003.02182-2018 Year: 2019
Pulmonary vasculitis: update on the management of ANCA-associated vasculitis Source: Eur Respir Mon; 2009: 46: 251–264 Year: 2009
The comparison of the manifestation of systemic inflammation in patients with minor forms of tuberculosis and pulmonary sarcoidosis Source: Annual Congress 2009 - Clinical tuberculosis Year: 2009
Predictors of exercise capacity in patients with pulmonary manifestations of primary small vessel vasculitis Source: Eur Respir J 2002; 20: Suppl. 38, 290s Year: 2002
Pulmonary manifestations of systemic vasculitis in childhood Source: Breathe, 16 (4) 200211; 10.1183/20734735.0211-2020 Year: 2020
Severe lung involvement in systemic scleromyxoedema: a highly unusual finding Source: Eur Respir J 2002; 19: 976-979 Year: 2002
Interstitial lung disease with usual interstitial pneumonia pattern preceding the presentation of ANCA-associated vasculitis by 4 years: coincidence or correlation? Source: Breathe, 14 (3) e105; 10.1183/20734735.017518 Year: 2018
Response to PAH specific therapy in systemic sclerosis patients with extensive parenchymal changes and pulmonary hypertension Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020
Acute exacerbation of idiopathic pulmonary fibrosis as the initial presentation of the disease Source: Eur Respir Rev 2009; 18: 129-132 Year: 2009
Histopathologic changes, cellular apoptosis, and pulmonary vasculitis, with related immunogenetic changes in schistosomal corpulmonale patients Source: Eur Respir J 2006; 28: Suppl. 50, 658s Year: 2006
Pulmonary manifestations in adult patients with chronic granulomatous disease Source: Eur Respir J 2015; 45: 1613-1623 Year: 2015
Features of pulmonary involvement in patients with diffuse connective tissue diseases depending on a nosological form Source: Annual Congress 2011 - Rare diffuse lung diseases Year: 2011
Clinical course and lung function change of idiopathic nonspecific interstitial pneumonia Source: Eur Respir J 2009; 33: 68-76 Year: 2009
Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease Source: Eur Respir Rev, 27 (148) 170102; 10.1183/16000617.0102-2017 Year: 2018
Interstitial lung disease Source: Eur Respir Rev 2013; 22: 26-32 Year: 2013
Clinical and laboratory features of systemic sclerosis with pulmonary involvement Source: Eur Respir J 2001; 18: Suppl. 33, 512s Year: 2001